Brain-targeting study of ketamine response in treatment-resistant depression
Treatments studied
Part of Mental health clinical trials.
This early-stage study looks at how parts of brain cells respond to ketamine in people with depression who have not improved with usual antidepressants. It may help researchers find why ketamine works for some people and not others, and who might benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are right-handed (using the Edinburgh Handedness test).
- You are currently experiencing depression, with a screening score above 17.
- Your depression has not improved after trying one or more appropriate antidepressant medications.
- You meet criteria for major depressive disorder (MDD) based on a structured interview.
- If you’ve used ketamine before, it must have helped reduce your depression symptoms; if not, you may not qualify for this part.
- For the week before each MRI scan, you will avoid caffeine and avoid alcohol/drugs (as instructed by the team).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether an “AMPA receptor blocker” changes how ketamine affects suicidal thoughts in people with depression that hasn’t improved with usual treatments. If you qualify, you may receive ketamine and the study medicine, while continuing your regular mental health care.
This study tests a new experimental drug (2R,6R)-HNK, a chemical related to ketamine, given by IV infusion to see if it can help people with depression that hasn't improved with other treatments. The goal is to find a new option for people who have not found relief from standard antidepressants.
This study tests how a single dose of ketamine affects certain brain and body markers in people with severe depression. It aims to find better ways to predict who will respond to ketamine, which may help personalize depression treatment in the future.
This trial studies how ketamine affects brain circuits in people with depression compared to healthy volunteers. It involves a single infusion of ketamine and brain scans before and after.
This trial tests whether a single dose of ketamine can quickly improve depression by studying brain chemical changes using MRI. It's for people with treatment-resistant depression who haven't used ketamine before.
This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.
Hear when a new PTSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.